| Literature DB >> 25229164 |
Antonio Valentin1, Katherine McKinnon2, Jinyao Li1, Margherita Rosati1, Viraj Kulkarni3, Guy R Pilkington3, Jenifer Bear3, Candido Alicea3, Diego A Vargas-Inchaustegui4, L Jean Patterson4, Poonam Pegu5, Namal P M Liyanage5, Shari N Gordon5, Monica Vaccari5, Yichuan Wang6, Alison E Hogg6, Blake Frey6, Yongjun Sui6, Steven G Reed7, Niranjan Y Sardesai8, Jay A Berzofsky6, Genoveffa Franchini5, Marjorie Robert-Guroff4, Barbara K Felber9, George N Pavlakis10.
Abstract
To identify the most promising vaccine candidates for combinatorial strategies, we compared five SIV vaccine platforms including recombinant canary pox virus ALVAC, replication-competent adenovirus type 5 host range mutant RepAd, DNA, modified vaccinia Ankara (MVA), peptides and protein in distinct combinations. Three regimens used viral vectors (prime or boost) and two regimens used plasmid DNA. Analysis at necropsy showed that the DNA-based vaccine regimens elicited significantly higher cellular responses against Gag and Env than any of the other vaccine platforms. The T cell responses induced by most vaccine regimens disseminated systemically into secondary lymphoid tissues (lymph nodes, spleen) and effector anatomical sites (including liver, vaginal tissue), indicative of their role in viral containment at the portal of entry. The cellular and reported humoral immune response data suggest that combination of DNA and viral vectors elicits a balanced immunity with strong and durable responses able to disseminate into relevant mucosal sites. Published by Elsevier Inc.Entities:
Keywords: Cellular immune response; DNA; Pox virus ALVAC MVA; Prime-boost vaccination; Protein
Mesh：
Substances：
Year: 2014 PMID： 25229164 PMCID： PMC4252823 DOI： 10.1016/j.clim.2014.09.005
Source DB: PubMed Journal: Clin Immunol ISSN： 1521-6616 Impact factor: 3.969